Vishal Gulati
Venture Partner @ Molten Ventures
London, United Kingdom
Vishal Gulati is a Series A investor at Molten Ventures in London focused on Biotechnology and Biopharma. Vishal Gulati is based out of Oxford, Oxfordshire, and is the Founder and Managing Partner of Recode Health Ventures and also serves as a Board of Directors of Sensible Biotechnologies. Vishal previously worked at Healthily as a Member of Clinical Advisory Board. Vishal Gulati attended Imperial College London. Vishal Gulati has been certified as a 100 Most Influential Health Tech Leaders 2016.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Vishal Gulati invests in
Stages Vishal Gulati invests in
Countries Vishal Gulati invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $3.3M–$8M
- Series A
- $2.4M–$27M
- Series B
- $7.1M–$30M
Investment Focus
Industry
- Biotechnology 6 (67%)
- Biopharma 3 (33%)
- Life Science 3 (33%)
- Pharmaceutical 2 (22%)
- Artificial Intelligence 2 (22%)
Stage
- Series A 3 (33%)
- Seed 2 (22%)
- Series B 2 (22%)
- Pre-Seed 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- United Kingdom 4 (44%)
- Hungary 1 (11%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines. | $27M / Series A / Oct 06, 2026 | ||
| Accelerate drug time to market through real study traceability and unparalleled trial integrity | $1.3M / Pre-Seed / Aug 17, 2023 | ||
| evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $30M / Series B / Mar 02, 2020 | ||
| Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer. | $3.3M / Seed / Nov 06, 2019 | ||
| Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic. | $8M / Seed / Jul 01, 2019 | ||
| evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $12.3M / Series A / Jan 30, 2018 | ||
| ieso is a provider of online mental health therapy and develops clinically evidenced assessment and treatment products. ieso's breakthrough discoveries transforms mental healthcare and is revolutionising how the world sees mental health.ieso is building globally scalable digital products and therapeutics for the assessment and treatment ofcommon mood disorders with an additional focus on behaviorally modifiable chronic diseases. | $23.9M / Venture - Series Unknown / Sep 12, 2017 | ||
| Fluidic Analytics was formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge.Their roots stretch back to a group of scientists who were inspired by the roles that proteins play in the biological world, driven to understand more about how proteins behave and function, but frustrated by the lack of suitabletools for protein characterisation. So they decided to invent their own.Their vision is that protein science will transform their understanding of how the biological world operates in real time. They believe that this transformation will be every bit as revolutionary as the way that advances in DNA sequencing have transformed their understanding of how the biological world operates over decades, lifetimes and generations. And they believe that Fluidic Analytics can help make this vision a reality by developing products that enable easier, faster, more convenient and more accurate protein characterisation, whether in the lab, at the bedside or in everyday life.They've combined cutting edge technology, a fantastic team and best practice in management and communication to go from their founding to a customer ready prototype in 2 years. And they’re only just beginning. This instrument is just the first step towards a platform technology that will serve as the interface between the biological and digital world – as they continue to expand what is possible for their customers.Their desire for accessibility and openness is present in their company’s culture of communication and integrity, in the usability of their products, in their open exchange of ideas with their collaborators and in their commitment to their users complete ownership of their own data. They believe that in working this way, they have the opportunity to create not just a company, but a community that fundamentally improves how they live. | $7.1M / Series B / Sep 06, 2016 | ||
| Fluidic Analytics was formed in 2013 as a spin-out from the Department of Chemistry at the University of Cambridge.Their roots stretch back to a group of scientists who were inspired by the roles that proteins play in the biological world, driven to understand more about how proteins behave and function, but frustrated by the lack of suitabletools for protein characterisation. So they decided to invent their own.Their vision is that protein science will transform their understanding of how the biological world operates in real time. They believe that this transformation will be every bit as revolutionary as the way that advances in DNA sequencing have transformed their understanding of how the biological world operates over decades, lifetimes and generations. And they believe that Fluidic Analytics can help make this vision a reality by developing products that enable easier, faster, more convenient and more accurate protein characterisation, whether in the lab, at the bedside or in everyday life.They've combined cutting edge technology, a fantastic team and best practice in management and communication to go from their founding to a customer ready prototype in 2 years. And they’re only just beginning. This instrument is just the first step towards a platform technology that will serve as the interface between the biological and digital world – as they continue to expand what is possible for their customers.Their desire for accessibility and openness is present in their company’s culture of communication and integrity, in the usability of their products, in their open exchange of ideas with their collaborators and in their commitment to their users complete ownership of their own data. They believe that in working this way, they have the opportunity to create not just a company, but a community that fundamentally improves how they live. | $2.4M / Series A / Dec 18, 2014 |
Co-Investors
About Molten Ventures
Molten Ventures is a leading British venture capital firm backing Europe’s highest-growth private technology companies. Our expert investment team stay ahead of the curve, identifying transformative trends and next-generation companies before they break through. We combine multiple pools of capital to invest at all stages of the business lifecycle—from seed and early stage to growth and late stage—focusing on disruptive sectors like Spacetech, Fintech, and AI. Our strategy is simple: back bold ideas, scale them with capital and expertise, and unlock high-value exits—whether through strategic acquisitions, trade buy-outs, or IPOs. Since our 2016 IPO, we’ve delivered strong realised returns, reinvesting into the next wave of innovation—creating a virtuous cycle of growth and value.
Molten Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan Duncan
Venture Partner
|
|||
David Cummings
Partner
|
|||
George Chalmers
Principal
|
|||
Inga Deakin
Principal
|
|||
John Marsh
Senior Partner, Venture Capital
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Vishal Gulati invest in?
Vishal Gulati invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Vishal Gulati invest in?
Vishal Gulati typically joins rounds of $3.3M–$8M at Seed, $2.4M–$27M at Series A and $7.1M–$30M at Series B. These are whole funding-round sizes, not Vishal Gulati's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Vishal Gulati took part in.
How do I contact Vishal Gulati?
Public channels for Vishal Gulati include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Vishal Gulati last invest?
The most recent investment recorded for Vishal Gulati closed in Oct 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
